Sungen Biomedical's Revolutionary SGC001 Antibody Drug Receives FDA Fast Track Approval Sungen Biomedical's SGC001, the first antibody for acute myocardial infarction, has been granted FDA Fast Track approval to enhance patient care.

Sungen Biomedical's Revolutionary SGC001 Antibody Drug Receives FDA Fast Track Approval #United_States #New_York #FDA_Fast_Track #Sungen_Biomedical #SGC001